摘要
目的探讨非诺贝特和吡格列酮干预对果糖饲养的代谢综合征(MS)大鼠血压及糖脂代谢的影响。方法构建高果糖饮食诱导的MS大鼠模型,分别单用非诺贝特(Fen)和吡格列酮(Pio)及二者合用干预。比较不同药物干预对MS大鼠收缩压(SBP)、空腹血糖(FBS)、空腹胰岛素(FINS)、血脂、胰岛素敏感指数(ISI)等指标的影响。结果 Pio和Fen干预均可降低MS大鼠的FINS、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、游离脂肪酸(FFA)水平,此外Pio还可降低MS大鼠的SBP、FBS水平,升高其ISI;而Fen可升高MS大鼠高密度脂蛋白胆固醇(HDL-C)水平;合用Pio和Fen,可降低MS大鼠的FBS、FINS、SBP、TG、CHO、LDL-C、FFA水平,升高其ISI和HDL-C水平。结论 Pio干预可改善其胰岛素抵抗(IR),降低MS大鼠的SBP,改善糖脂代谢。Fen干预能改善MS大鼠脂代谢,但对血压及糖代谢影响不明显。合用Pio和Fen干预,可显著改善MS大鼠RI、降低SBP及纠正其糖脂代谢紊乱,更好地控制其心血管病的危险因素。
【Objective】 To explore the effect of fenofibrate and pioglitazone on blood pressure,blood glucose and lipid metabolism in rats with fructose-induced metabolic syndrome（MS）.【Methods】 SD rat was bred with high fructose-food to build MS rat model,and fenofibrate or pioglitazone was used singly or in combination to intervene MS rats.The systolic blood pressure（SBP）,and the levels of fasting blood sugar（FBS）,fasting insulin（FINS）,serum lipid and insulin sensitivity index（ISI） were analyzed and compared among groups with different interventions.【Results】 The SBP and the levels of FBS,FINS,serum triglyceride（TG）,serum cholesterol（CHO）,serum low density lipoprotein-cholesterol（LDL-C） and serum free fatty acids（FFA） were decreased and ISI were increased in MS rats treated by pioglitazone;and the levels of FINS,TG,LDL-C and FFA were decreased and high density lipoprotein-cholesterol（HDL-C） were increased in MS rats,but there were no significant influence on SBP and FBS of MS rats treated by fenofibrate.After combined treatment with fenofibrate and pioglitazone,the SBP and the levels of FBS,FINS,TG,CHO,LDL-C and FFA in MS rats were decreased,and the levels of ISI and HDL-C were ascended.【Conclusion】 Intervention with pioglitazone can lower SBP and improve insulin resistance,blood sugar and lipid metabolism,while that with fenofibrate can improve lipid metabolism,but there is no significant influence on SBP and blood sugar in MS rats.All of the RI,SBP and blood sugar and lipid metabolism of MS rats are improved by intervention with combination of fenofibrate and pioglitazone,which can control the risk factors of cardiovascular diseases preferably.
出处
《中国现代医学杂志》
CAS
CSCD
北大核心
2010年第6期801-804,809,共5页
China Journal of Modern Medicine
基金
深圳市科技基金重点资助项目(No:200643)
